Retroperitoneal fibrosis in a patient with Parkinson's disease treated with pergolide.
We describe a 68-year-old patient with Parkinson's disease who developed retroperitoneal fibrosis during pergolide treatment. Because pergolide is an ergot derivative, it could be related to the development of this complication.
Jiménez-Jiménez
F J
FJ
Department of Neurology, Hospital Príncipe de Asturias, Alcalá de Henares (Madrid), Spain.
López-Alvarez
J
J
Sánchez-Chapado
M
M
Montero
E
E
Miquel
J
J
Sierra
A
A
Gutiérrez
F
F
D000368:Aged; D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy*; D010479:Pergolide / Q000009:adverse effects* / Q000627:therapeutic use*; D012185:Retroperitoneal Fibrosis / Q000139:chemically induced* / Q000150:complications
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D010479:Pergolide